345902-20-7

Upstream product

• 1620955-38-5 C₂₀H₁₉BrN₂O₂ 
• 99-90-1 para-bromoacetophenone 
• 91-56-5 indole-2,3-dione 
• 351982-02-0 ethyl 2-(4'-bromophenyl)-quinoline-4-carboxylate 
• 859929-64-9 2-(4-bromo-phenyl)-quinoline-4-carbonyl azide 
• 351899-02-0 2-(4-bromophenyl)quinoline-4-carboxylic acid hydrazide 
• 103914-52-9 2-(4'-bromophenyl)quinoline-4-carboxylic acid 
• 260351-31-3 2-(4-bromophenyl)-1-methanesulfonyl-1,2,3,4-tetrahydroquinolin-4-one 
• 856086-95-8 [2-(4-bromo-phenyl)-[4]quinolyl]-carbamic acid ethyl ester 

Downstream Products

• 1620955-40-9 C₁₇H₁₄BrN₃O 
• 1620955-41-0 C₁₈H₁₂BrN₃O₂ 
• 1620955-42-1 C₃₃H₃₃N₃O₅ 
• 1620955-43-2 3-(2-(4'-(4-hydroxybutoxy)-[1,1'-biphenyl]-4-yl)quinolin-4-yl)imidazolidine-2,4-dione hydrochloride 
• 1620955-39-6 C₂₂H₂₂BrN₃O₃ 

Relevant academic research and scientific papers

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Unprecedented outcome of base-promoted neber rearrangement of O-Mesyloxime of 2-aryl-1,2,3,4-tetrahydro-1-methylsul fonyl-4-quinolone-synthesis of 4-amino-2-arylquinolines

O-Mesyloximes derived from 2-aryl-1,2,3,4-tetrahydro-1-methylsulfonyl-4-quinolones react with sodium ethoxide in ethanol to afford the 4-amino-2-arylquinolines in high yield. No traces of the 3-amino-2-aryl-4-quinolones expected from the Neber rearrangeme